ANALYSIS OF THE WORK OF A MULTIDISCIPLINARY GROUPIN THE TREATMENT OF LUNG CANCER IN THE TURKESTAN REGIONFOR 2019-2020

Abstract

Introduction: The introduction of a multidisciplinary approach to the treatment of lung cancer has now become very
much in demand, since the precise determination of the molecular and biological characteristics of the tumor, before the start
of treatment, allows for a significant improvement in the results of increasing overall and relapse-free survival.
The aim of the study is to analyze the performance of a multidisciplinary group in the treatment of lung cancer and to
study mutations in the EGFR, ALK gene in the Turkestan region for 2019-2020.
Materials and methods: The study is a retrospective observational one. An analysis was made of the performance
indicators of a multidisciplinary group working on the basis of the oncological center of the Turkestan region for 2019-
2020.During the study period, 391 patients were examined by a multidisciplinary group. The analyzed indicators were:
patient's age, gender, histological data, diagnosis, stages, types of treatment. 

All statistical calculations were performed using the SPSS program (version 25.0, IBM SPSS Inc., Chicago, USA).The
data were summarized using descriptive statistics methods.
Statistical processing of the obtained data was carried out using Microsoft Excel, the average value was determined. The
data were summarized using descriptive statistics methods.
Results: The largest number of patients with lung cancer were referred for combined treatment, palliative chemotherapy,
targeted therapy. In 2020, compared to 2019, the percentage of combination therapy increased by 3%, and the percentage
of targeted therapy increased by 4%. Mutations of the EGFR gene were detected, of which Ex19del, L858R, Ex20Ins,
T790M were detected.
Conclusion: For the first time, an analysis of the work of MDG in the treatment of lung cancer in the Turkestan region for
2019-2020 was carried out. Improved diagnostics of indicators of molecular genetic studies in the EGFR gene, ALK-positive
metastatic non-small cell lung cancer, which made it possible to optimize the choice of personalized treatment tactics for
patients and refer them to combined treatment, palliative chemotherapy and targeted therapy, which reduced the number of
registrations of new cases of advanced lung cancer.